Two stocks in Healthcare
Lonza Group vs Zealand Pharma A/S: profit, growth, debt and price compared
Lonza Group is stronger on 3 of 6 figures: sales growth, price for its expected profit and price trend. Zealand Pharma A/S is stronger on 2: profit margin and debt.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Lonza GroupLONN.SW | Zealand Pharma A/SZEAL.CO | |
|---|---|---|
| Net margin | −1.6% | Stronger: 67.2% |
| Revenue growth, past year | Stronger: +11.20% | −92.00% |
| Debt to equity | 51.1% | Stronger: 2.8% |
| Forward P/E | Stronger: 29.7× | 30.7× |
| Dividend yield | 0.75% | — |
| Analysts | Buy · 23 | Buy · 12 |
| From its 200-day average | Stronger: +17.8% | −28.0% |
Share price over the past year
- Lonza Group+23.6%
- Zealand Pharma A/S−57.7%
17 Nov 202518 Nov 2026
Lonza Group or Zealand Pharma A/S: which is stronger?
- ZEAL.CO
Which is more profitable?
Zealand Pharma A/S keeps more of each sale as profit: 67.2% against −1.6%.
- LONN.SW
Which is growing its sales faster?
Lonza Group is growing its sales faster: +11.20% over the past year, against −92.00%.
- ZEAL.CO
Which has borrowed less?
Zealand Pharma A/S has borrowed less: its debt is 2.8% of what its shareholders own, against 51.1% for Lonza Group.
- LONN.SW
Which costs less for the profit it is expected to make?
Lonza Group costs less for the profit it is expected to make: 29.7× its forward earnings, against 30.7×.
Which pays more in dividends?
Lonza Group pays 0.75% a year in dividends for what a share costs, where Zealand Pharma A/S pays none.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- LONN.SW
Which is in the stronger price trend?
Lonza Group's price is in the stronger trend: 17.8% above its 200-day average, against 28.0% below.
What each company does
LONN.SWLonza Group
Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, and internationally.
Reports results on 27 January 2027
ZEAL.COZealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.